BridgeBio Pharma: A Rising Star in the Pharmaceutical Industry
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a cutting-edge pharmaceutical company that is focused on identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Founded in 2015 by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in Palo Alto, CA, the company has quickly become a major player in the healthcare industry.
With an impressive pipeline of development programs that includes product candidates ranging from early discovery to late-stage development, BridgeBio Pharma has garnered the attention of institutional investors and hedge funds alike. According to Bloomberg.com, the company has recently been assigned a consensus recommendation of “Buy” from ten ratings firms that are presently covering the stock. Eight research analysts have rated the stock with a buy rating.
The average 12-month price target among brokers that have issued ratings on the stock in the last year is $26.63, indicating a solid potential for growth over the coming months. Indeed, several institutional investors have already made changes to their positions in anticipation of this growth.
Notably, Bank of New York Mellon Corp grew its stake in BridgeBio Pharma by 3.2% in the 1st quarter. MetLife Investment Management LLC also increased its stake in shares of BridgeBio Pharma by 52.5% during the same period while Vanguard Group Inc lifted its holdings by 1%. Additionally, XTX Topco Ltd acquired a new stake in shares of BridgeBio Pharma worth approximately $153,000.
Overall, it seems as though BridgeBio Pharma is well-positioned for continued success in the years ahead thanks to its innovative products and rapidly-expanding network of institutional investors. With an unwavering commitment to improving patient outcomes and developing new treatments for even the most complex of illnesses, there’s no telling what breakthroughs this exciting company may soon be able to achieve!
BridgeBio Pharma, Inc.
BBIO
Neutral
Updated on: 12/06/2023
Price Target
Show more
Social Sentiments
2:00 PM (UTC)
Date:12 June, 2023
0
Twitter Sentiment
0
Stocktwits Sentiment
Show more
Analyst Ratings
| Analyst / firm | Rating |
|---|---|
| J.P. Morgan | Buy |
|
Dane Leone Raymond James |
Buy |
Show more
BridgeBio Pharma Surges in Stock Value as Research Reports Drive Investor Interest
BridgeBio Pharma Raises Interest as Research Reports Pour In
BridgeBio Pharma, Inc. is quickly gaining attention from investors and industry professionals alike, thanks to a flurry of recent research reports boosting the company’s target price and rating. JPMorgan Chase & Co, Bank of America Merrill Lynch, Raymond James, The Goldman Sachs Group and Mizuho all released reports throughout March and May adjusting their ratings on the therapeutic medicine development firm.
JPMorgan Chase upped their target price from $18 to $23 while marking the stock “overweight”. Meanwhile, Raymond James marked BridgeBio Pharma an “outperform” while increasing its target price to $29 from the previous $17. Strikingly similar was Bank of America’s Marking BridgeBio’s share value a $3 increase with a new figure of $18. Both The Goldman Sachs Group and Mizuho agreed with Raymond James in changing their target prices from $20 to $28 for The Goldman Sachs Group, and elevating Mizuho’s projected value from $23 to $29.
CFO Brian C. Stephenson also recently made waves in the pharmaceutical industry after selling 55,500 shares at an average cost of $15.45 per share earlier this year with Neil Kumar following suite by dumping 120,000 shares at an average cost of ten cents more than Stephenson’s figures.
Investors taking note of BridgeBio Pharma will find that it is focused primarily on innovation and transformational medicines that aim to treat Mendelian diseases: genetic disorders caused by just one faulty gene copy inherited at birth. And while initial fears surrounding these innovations were that they would be prohibitively expensive both for patients and insurance companies alike, BridgeBio’s product candidates span early discovery stages through late-stage development meaning costs are likelier skewed toward the former than latter end of things.
Despite some recent setbacks where Q1 earnings missed estimates by $0.009 cents per share ($0.92 versus estimated $0.83), BridgeBio Pharma has seen its revenue rise and was valued at $2.57bn with a PE ratio of -5.63 and a beta of 0.71 on the NASDAQ stock exchange as of Friday last week with analysts expecting it to post negative EPS figures for the current financial year.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source